Dennis Kim, MD, PhD

My research is aiming to develop projects of: 1) biomarker discovery using genomics in leukemias and allogeneic stem cell transplantation; and 2) clinical research in chronic myeloid leukemia and graft-versus-host disease after allogeneic stem cell transplantation.

I have also been involved in multiple exome sequencing projects in acute myleoid leukemia (AML) with normal karyotype and secondary AML progressed from antecedent hematologic malignancies, as well as chronic myeloid leukemia (CML). My future direction of genomic research is to integrate multi-omics platforms to investigate leukemia genomes, thus dissecting clonal structures in a refined way.

Not only in translational research, but also in the clinical research field, I have shown significant progress in three ways: 1) clinical database registry; 2) retrospective studies using the database; and 3) generation of prospective clinical trials in CML and in graft-versus-host disease (GVHD) and other post-transplant complications after allogeneic stem cell transplantation.  First of all, I developed a clinical database of allogeneic transplant patients (especially for GVHD and post-transplant complications) and CML patients (especially for treatment outcomes after tyrosine kinase inhibitor therapy). Secondly, I have participated in multiple ongoing clinical retrospective studies generated from the registry database. Thirdly, I am involved in  multiple clinical trials. Currently, I am the principal investigator of a pivotal Canadian tyrosine kinase inhibitor (TKI) discontinuation clinical trial and am also a chair of the correlative part of this trial, entitled "Treatment-free Remission Accomplished with Dasatinib (TRAD)". This is the first Canadian TKI discontinutation trial for the management of CML.
PLoS One. 2019;14(6):e0218968
Woo YM, Kim S, Park JH, Lee NY, Kim JW, Kim DDH
Leukemia. 2019 Jun 17;:
Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, Radich JP, Hochhaus A, Hughes TP, International CML Foundation Genomics Alliance
Exp Hematol. 2019 Jun 12;:
Ahn JS, Kim T, Kim YK, Cho YC, Cho S, Jung SH, Ahn SY, Jung SY, Yang DH, Lee JJ, Choi S, Lee JY, Shin MG, Yoshida K, Ogawa S, Kim IC, Zhang Z, Kim HJ, Kim DDH
Biol Blood Marrow Transplant. 2019 Jun 04;:
Shapiro RM, Shin E, Law AD, Lam W, Michelis FV, Viswabandya A, Kumar R, Lipton JH, Messner H, Mattsson J, Kim DDH
Biol Blood Marrow Transplant. 2019 May 31;:
Hamilton BK, Liu Y, Hemmer MT, Majhail N, Ringden O, Kim D, Costa L, Stuart R, Alousi A, Pidala JA, Couriel DR, Aljurf M, Antin JH, Bredeson C, Cahn JY, Cairo M, Choi SW, Dandoy C, Gale RP, Gergis U, Hematti P, Inamoto Y, Kamble RT, MacMillan M, Marks...
Eur J Haematol. 2019 Jun;102(6):486-493
Prem S, Atenafu EG, Al-Shaibani Z, Loach D, Law A, Lam W, Michelis FV, Thyagu S, Kim DDH, Howard Lipton J, Kumar R, Viswabandya A
J Clin Med. 2019 Feb 24;8(2):
Warburton DER, Bredin SSD, Shellington EM, Cole C, de Faye A, Harris J, Kim DD, Abelsohn A
Eur J Haematol. 2019 Jan 31;:
Pasic I, Da'na W, Lam W, Law A, Lipton JH, Viswabandya A, Kim DD, Thyagu S, Messner HA, Michelis FV
Biol Blood Marrow Transplant. 2019 Jan 14;:
Michelis FV, Hedley DW, Malhotra S, Chow S, Loach D, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Viswabandya A, Messner HA
Leukemia. 2018 Dec 16;:
Park JH, Woo YM, Youm EM, Hamad N, Won HH, Naka K, Park EJ, Park JH, Kim HJ, Kim SH, Kim HJ, Ahn JS, Sohn SK, Moon JH, Jung CW, Park S, Lipton JH, Kimura S, Kim JW, Kim DDH

Pages